- Home
- PMO vs TERN Comparison
PMO vs TERN Comparison
Compare PMO & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMO
- TERN
- Stock Information
- Founded
- PMO 1993
- TERN 2017
- Country
- PMO United States
- TERN United States
- Employees
- PMO N/A
- TERN N/A
- Industry
- PMO Finance Companies
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- PMO Finance
- TERN Health Care
- Exchange
- PMO Nasdaq
- TERN Nasdaq
- Market Cap
- PMO 287.4M
- TERN 262.9M
- IPO Year
- PMO N/A
- TERN 2021
- Fundamental
- Price
- PMO $9.77
- TERN $3.54
- Analyst Decision
- PMO
- TERN Buy
- Analyst Count
- PMO 0
- TERN 5
- Target Price
- PMO N/A
- TERN $15.63
- AVG Volume (30 Days)
- PMO 99.0K
- TERN 692.5K
- Earning Date
- PMO 01-01-0001
- TERN 05-08-2025
- Dividend Yield
- PMO 4.10%
- TERN N/A
- EPS Growth
- PMO N/A
- TERN N/A
- EPS
- PMO 0.42
- TERN N/A
- Revenue
- PMO N/A
- TERN N/A
- Revenue This Year
- PMO N/A
- TERN N/A
- Revenue Next Year
- PMO N/A
- TERN N/A
- P/E Ratio
- PMO $24.38
- TERN N/A
- Revenue Growth
- PMO N/A
- TERN N/A
- 52 Week Low
- PMO $8.57
- TERN $1.87
- 52 Week High
- PMO $10.68
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- PMO 41.20
- TERN 67.52
- Support Level
- PMO $9.73
- TERN $3.01
- Resistance Level
- PMO $9.84
- TERN $3.60
- Average True Range (ATR)
- PMO 0.10
- TERN 0.21
- MACD
- PMO -0.02
- TERN 0.06
- Stochastic Oscillator
- PMO 9.76
- TERN 91.33
About PMO Putnam Municipal Opportunities Trust
Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.